BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36484700)

  • 21. FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.
    Li F; Niu M; Qin K; Guo R; Yi Y; Xu J; Li L; Xie S; Fu M; Wen N; Liao W; Xiao ZJ
    Oncogene; 2023 Jan; 42(5):339-350. PubMed ID: 36460773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
    Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
    Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.
    Wang S; Akhtar J; Wang Z
    Tumour Biol; 2015 Sep; 36(10):7797-806. PubMed ID: 25944168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.
    Long L; Xu J; Qi X; Pen Y; Wang C; Jiang W; Peng X; Hu Z; Yi W; Xie L; Lei X; Wang Z; Zhuo L
    Eur J Med Chem; 2024 Jul; 273():116500. PubMed ID: 38776807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis.
    Liu S; González-Prieto R; Zhang M; Geurink PP; Kooij R; Iyengar PV; van Dinther M; Bos E; Zhang X; Le Dévédec SE; van de Water B; Koning RI; Zhu HJ; Mesker WE; Vertegaal ACO; Ovaa H; Zhang L; Martens JWM; Ten Dijke P
    Clin Cancer Res; 2020 Mar; 26(6):1460-1473. PubMed ID: 31857432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
    Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
    J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer.
    Jaiswal A; Murakami K; Elia A; Shibahara Y; Done SJ; Wood SA; Donato NJ; Ohashi PS; Reedijk M
    Proc Natl Acad Sci U S A; 2021 Sep; 118(38):. PubMed ID: 34518219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
    Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
    Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
    [No Abstract]   [Full Text] [Related]  

  • 34. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
    Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
    Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
    Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
    Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
    Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers.
    Liu J; Li J; Wang K; Liu H; Sun J; Zhao X; Yu Y; Qiao Y; Wu Y; Zhang X; Zhang R; Yang A
    Signal Transduct Target Ther; 2021 Feb; 6(1):42. PubMed ID: 33526768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer.
    Xiong H; Yan T; Zhang W; Shi F; Jiang X; Wang X; Li S; Chen Y; Chen C; Zhu Y
    Cell Signal; 2018 Apr; 44():33-42. PubMed ID: 29339084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro assessment of roles of PPP1R14B in cervical and endometrial cancer.
    Xiang N; Chen T; Zhao X; Zhao M
    Tissue Cell; 2022 Aug; 77():101845. PubMed ID: 35679681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.